日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure.

AHSA1-HSP90AA1 复合物稳定 IFI6 和 TGFB1,促进 EGFR 突变肺腺癌在奥希替尼压力下的线粒体稳定性和 EMT

Sui Ying, Shen Ziyang, Pan Rongtian, Ma Rong, Si Rujia, Feng Jifeng, Zhou Guoren

Lactylation in cancer: metabolic mechanism and therapeutic strategies

癌症中的泌乳作用:代谢机制和治疗策略

Sui, Ying; Shen, Ziyang; Wang, Zhenling; Feng, Jifeng; Zhou, Guoren

The systemic oxidative stress index predicts clinical outcomes of esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

系统性氧化应激指数可预测接受新辅助免疫化疗的食管鳞状细胞癌患者的临床结果

Feng, Jifeng; Wang, Liang; Yang, Xun; Chen, Qixun

Pretreatment immune-inflammatory prognostic score in predicting clinical outcomes in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

新辅助免疫化疗治疗食管鳞状细胞癌患者的预处理免疫炎症预后评分对临床结局的预测价值

Zhao, Qiang; Wang, Liang; Yang, Xun; Feng, Jifeng; Chen, Qixun

Serum creatinine to cystatin C ratio is a prognostic indicator in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy

血清肌酐与胱抑素C比值是接受新辅助免疫化疗的食管鳞状细胞癌患者的预后指标。

Feng, Jifeng; Wang, Liang; Yang, Xun; Chen, Qixun

Famitinib plus camrelizumab in patients with advanced colorectal cancer: Data from a multicenter, basket study

法米替尼联合卡瑞利珠单抗治疗晚期结直肠癌患者:一项多中心篮式研究的数据

Ai, Luoyan; Li, Qian; Zhang, Shilong; Dong, Yu; Yang, Mudan; Li, Jin; Pan, Yueyin; Yuan, Ying; Yi, Shanyong; Wang, Junsheng; Cheng, Ying; Feng, Jifeng; Gao, Shegan; Wang, Xicheng; Qu, Song; Zhang, Xizhi; Lu, Jin; Xiu, Peng; Wang, Shuni; Yang, Xinfeng; Yu, Yiyi; Liu, Tianshu

Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial

伊沃内西单抗联合化疗治疗EGFR变异型非小细胞肺癌:一项随机临床试验

Fang, Wenfeng; Zhao, Yuanyuan; Luo, Yongzhong; Yang, Runxiang; Huang, Yan; He, Zhiyong; Zhao, Hui; Li, Mingjun; Li, Kai; Song, Qibin; Du, Xiaobo; Sun, Yulan; Li, Wei; Xu, Fei; Wang, Zhiyu; Yang, Kunning; Fan, Yun; Liu, Baogang; Zhao, Hongyun; Hu, Ying; Jia, Li; Xu, Shen; Yi, Tienan; Lv, Dongqing; Lan, Haitao; Li, Mengxia; Liang, Wenhua; Wang, Yongsheng; Yang, Hui; Jia, Yuming; Chen, Yuan; Lu, Junguo; Feng, Jifeng; Liu, Chunling; Zhou, Ming; Zhou, Jianya; Liu, Xianling; Zhou, Ningning; He, Ming; Dong, Xiaorong; Chen, Hualin; Chen, Yongxing; Su, Haichuan; Li, Xiaoling; Zhang, Zhihong; Yang, Lei; Cheng, Ying; Chen, Likun; Hou, Xue; Zhang, Yu; Guo, Jun; Wang, Zhen; Lu, Hong; Wu, Di; Feng, Weineng; Li, Wen; Huang, Jianan; Wang, Yan; Song, Xia; Peng, Jiewen; Liu, Laiyu; Guo, Yubiao; Li, Wenting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhang, Li

Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma

新型口服PI3Kα/δ抑制剂TQ-B3525治疗复发和/或难治性滤泡性淋巴瘤的II期研究

Wang, Huaqing; Feng, Jifeng; Liu, Yanyan; Qian, Zhengzi; Gao, Da; Ran, Xuehong; Zhou, Hui; Liu, Lihong; Wang, Binghua; Fang, Meiyun; Zhou, Hebing; Huang, Zhenqian; Tao, Shi; Chen, Zhuowen; Su, Liping; Su, Hang; Yang, Yu; Xie, Xiaobao; Wu, Huijing; Sun, Ping; Hu, Guoyu; Liang, Aibin; Li, Zhiming

Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib study

Disitamab vedotin(一种靶向 HER2 的抗体药物偶联物)用于治疗 HER2 过表达和 HER2 低表达的晚期乳腺癌患者:一项 I/Ib 期研究

Wang, Jiayu; Liu, Yunjiang; Zhang, Qingyuan; Li, Wei; Feng, Jifeng; Wang, Xiaojia; Fang, Jianmin; Han, Yiqun; Xu, Binghe

Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)

奥莫替尼与吉非替尼治疗未经治疗的 EGFR 突变晚期非小细胞肺癌患者的中枢神经系统疗效:一项随机 III 期试验 (AENEAS) 的数据

Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Weng, Jie; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Wei, Hongying; Wei, Jiawei; Zhang, Zheyu; Wu, Qiong